Routine screening for placenta accreta spectrum

Screening for clinically significant placenta accreta spectrum (PAS) is possible with a high degree of accuracy (both sensitivity and specificity >90e95%). The group of women to focus on are those with placenta previa and one or more prior Cesarean deliveries. Screening for PAS not associated with placenta previa is not as productive, and several false negatives have been described. The results of the screening program indicate that women have a low or high probability of PAS. Screen-positive women or those with uncertain ultrasound features should be referred to a center of excellence. Those confirmed to have a high probability of PAS should electively be delivered at such centers. & COPY; 2023 The Author. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).

Automated summary

Screening for clinically significant placenta accreta spectrum (PAS) can accurately identify the condition with high sensitivity and specificity (>90-95%). The focus should be on women with placenta previa and previous Cesarean deliveries, as screening for PAS without placenta previa is less productive and may result in false negatives. Screening results can indicate a low or high probability of PAS, and women who test positive or have uncertain ultrasound features should be referred to specialized centers. Those confirmed with a high probability of PAS should plan for delivery at such centers.